Skip to main content
Jeffery S. Russell
( out of 138 reviews )

Jeffery S. Russell, MD, PhD, MBA

Languages spoken: English

Clinical Locations

  • Dr. Russell is a medical oncologist who treats patients with head and neck, endocrine, cutaneous, and other rare or unknown primary malignancies. After his oncology fellowship at Stanford University, he started his practice at Moffit Cancer Center in Tampa, FL and then spent a few years working in the pharmaceutical industry helping to develop cutting-edge immune therapy treatments that have been evaluated in early phase clinical trials and are now approved by the FDA. He joined Huntsman Cancer Institute in 2021 where he continues to treat head and neck, endocrine, cutaneous, and rare malignancies. He is engaged in clinical trial development with a focus on immune cellular therapy in solid tumors as well as research in N-Ras melanoma, immunosuppressed cutaneous squamous cell cancer, adrenocortical cancer, and salivary gland cancers.

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    5.0 /5
    ( out of 138 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    March 21, 2024
    HUNTSMAN CANCER CENTER

    Dr. Russell provides well informed compassionate care. Every detail of his treatment plan for me was executed and meticulously arranged for the best outcome possible.

    March 14, 2024
    HUNTSMAN CANCER CENTER

    Dr. Russell is averaging caring and compassionate doctor. I¿m blessed to have him on my care team.

    March 05, 2024
    SOUTH JORDAN HEALTH CENTER

    Dr, Russell is candid about my condition and explains the options. He is clear and always pauses for questions. He promptly addresses any concerns or questions via e-mail also. His answers for side-effect questions have helped me to cope with treatment. Mostly, I have confidence in his care. That means a great deal to me on this journey.

    March 01, 2024
    HUNTSMAN CANCER CENTER

    Dr Russell is literally a lifesaver. The immunotherapy he recommended has reduced all of the tumors in my lungs and completely eliminated most of them.

    February 15, 2024
    HUNTSMAN CANCER CENTER

    Dr. Russell is kind, attentive, compassionate, knowledgeable, and I¿m so grateful to be under his care through such a difficult journey.

    February 08, 2024
    HUNTSMAN CANCER CENTER

    Dr. Russell is brilliant, compassionate and easy to communicate with. In a time where many doctors seem to be too busy to fully listen and communicate Dr. Russell is Not that doctor! The best for what can be the worst time with a cancer diagnosis.

    January 28, 2024
    HUNTSMAN CANCER CENTER

    He is very conscientious and does a very good job

    January 26, 2024
    HUNTSMAN CANCER CENTER

    Jeffrey Russell is a great cancer doctor he knows his stuff and I thank him with my cancer that I had

    January 10, 2024
    SOUTH JORDAN HEALTH CENTER

    I am so grateful & incredibly fortunate to have Dr. Russell as my oncologist. I couldn't feel any better about the care I have received from him.

  • Dr. Russell is a medical oncologist who treats patients with head and neck, endocrine, cutaneous, and other rare or unknown primary malignancies. After his oncology fellowship at Stanford University, he started his practice at Moffit Cancer Center in Tampa, FL and then spent a few years working in the pharmaceutical industry helping to develop cutting-edge immune therapy treatments that have been evaluated in early phase clinical trials and are now approved by the FDA. He joined Huntsman Cancer Institute in 2021 where he continues to treat head and neck, endocrine, cutaneous, and rare malignancies. He is engaged in clinical trial development with a focus on immune cellular therapy in solid tumors as well as research in N-Ras melanoma, immunosuppressed cutaneous squamous cell cancer, adrenocortical cancer, and salivary gland cancers.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Graduate Training Strategic Management - Temple University M.B.A.
    Medical Oncology - Stanford University School of Medicine Fellow
    Internship/Residency Internal Medicine - University of California, San Francisco School of Medicine Intern/Resident
    Medicine - University of Texas Health Science Center at San Antonio M.D.
    Graduate Training Biomedical Sciences/Radiation Biology - University of Texas Health Science Center at Houston, University of Texas MD Anderson Cancer Center Ph.D.
    Biomedical Engineering - University of Miami M.S.
    Undergraduate Electrical Engineering - University of Kansas B.S.

    Selected Publications

    Journal Article

    1. Chari, A, Minnema, M, Berdeja, J, et al (2022). Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med, 387(24), 2232-2244.
    2. Kim, S, Wuthrick, E, Blakaj, D, et al (2022). Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet, 400(10357), 1008-1019.
    3. Girgis, S, Lin, S, Pillarisetti, K, et al (2022). Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma. Blood Adv.
    4. Lambert J, Marrel A, DAngelo SP, Burgess MA, Chmielowski B, Fazio N, Gambichler T, Grob JJ, Lebb C, Robert C, Russell J, Gzel G, Bharmal M (2020). Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. Patient, 13(4), 457-467. (Read full article)
    5. Knepper TC, Montesion M, Russell JS, Sokol ES, Frampton GM, Miller VA, Albacker LA, McLeod HL, Eroglu Z, Khushalani NI, Sondak VK, Messina JL, Schell MJ, DeCaprio JA, Tsai KY, Brohl AS (2019). The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res, 25(19), 5961-5971. (Read full article)
    6. Wang HL, McMillan SC, Vijayakumar N, McDonald S, Huang LT, Gwede C, Padhya T, Russell J, Vondruska K, Buck HG, Huang Y, Visovsky C (2018). A Behavioral Physical Activity Intervention to Manage Moderate and Severe Fatigue Among Head and Neck Cancer Patients-Pre-efficacy Study in the National Institutes of Health ORBIT Model. Cancer Nurs, 42(1), E1-E14. (Read full article)
    7. Naghavi AO, Echevarria MI, Strom TJ, Abuodeh YA, Venkat PS, Ahmed KA, Demetriou S, Frakes JM, Kim Y, Kish JA, Russell JS, Otto KJ, Chung CH, Harrison LB, Trotti A, Caudell JJ (2018). Patient choice for high-volume center radiation impacts head and neck cancer outcome. Cancer Med, 7(10), 4964-4979. (Read full article)
    8. DAngelo SP, Russell J, Lebb C, Chmielowski B, Gambichler T, Grob JJ, Kiecker F, Rabinowits G, Terheyden P, Zwiener I, Bajars M, Hennessy M, Kaufman HL (2018). Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncol, 4(9), e180077. (Read full article)
    9. Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, DAngelo SP, Shih KC, Lebb C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P (2018). Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer, 6(1), 7. (Read full article)
    10. Ross JS, Gay LM, Wang K, Vergilio JA, Suh J, Ramkissoon S, Somerset H, Johnson JM, Russell J, Ali S, Schrock AB, Fabrizio D, Frampton G, Miller V, Stephens PJ, Elvin JA, Bowles DW (2017). Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Ann Oncol, 28(10), 2539-2546. (Read full article)
    11. Knepper TC, Freeman ML, Gibney GT, McLeod HL, Russell JS (2017). Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma. JAMA Dermatol, 153(6), 607-609. (Read full article)
    12. Strom T, Naghavi AO, Messina JL, Kim S, Torres-Roca JF, Russell J, Sondak VK, Padhya TA, Trotti AM, Caudell JJ, Harrison LB (2016). Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck. Head Neck, 39(1), 48-55. (Read full article)
    13. Strom TJ, Naghavi AO, Trotti AM, Russell J, Kish JA, McCaffrey J, Otto KJ, Harrison LB, Caudell JJ (2016). Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years. J Geriatr Oncol, 8(1), 50-55. (Read full article)
    14. Wang K, Russell JS, McDermott JD, Elvin JA, Khaira D, Johnson A, Jennings TA, Ali SM, Murray M, Marshall C, Oldham DS, Washburn D, Wong SJ, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Serracino HS, Ross JS, Bowles DW (2016). Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations. Clin Cancer Res, 22(24), 6061-6068. (Read full article)
    15. Lowry PA, Freeman ML, Russell JS (2016). Nursing Management of Advanced Merkel Cell Carcinoma. Oncol Nurs Forum, 43(6), 680-683. (Read full article)
    16. Strom T, Carr M, Zager JS, Naghavi A, Smith FO, Cruse CW, Messina JL, Russell J, Rao NG, Fulp W, Kim S, Torres-Roca JF, Padhya TA, Sondak VK, Trotti AM, Harrison LB, Caudell JJ (2016). Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. Ann Surg Oncol, 23(11), 3572-3578. (Read full article)
    17. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, DAngelo SP, Shih KC, Lebb C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P (2016). Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol, 17(10), 1374-1385. (Read full article)
    18. Valderrabano P, Montilla-Soler J, Mifsud M, Leon M, Centeno B, Khazai L, Padhya T, McCaffrey T, Russell J, McIver B, Otto K (2016). Hypermetabolism on (18)F-Fluorodeoxyglucose Positron Emission Tomography Scan Does Not Influence the Interpretation of Thyroid Cytopathology, and Nodules with a SUVmax <2.5 Are Not at Increased Risk for Malignancy. Thyroid, 26(9), 1300-7. (Read full article)
    19. Valderrabano P, Leon ME, Centeno BA, Otto KJ, Khazai L, McCaffrey JC, Russell JS, McIver B (2016). Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests. Eur J Endocrinol, 174(5), 621-9. (Read full article)
    20. Frakes JM, Naghavi AO, Demetriou SK, Strom TJ, Russell JS, Kish JA, McCaffrey JC, Otto KJ, Padhya TA, Harrison LB, Trotti AM, Caudell JJ (2015). Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer. Cancer, 122(4), 634-41. (Read full article)
    21. Strom TJ, Trotti AM, Kish J, Russell JS, Rao NG, McCaffrey J, Padhya TA, Otto KJ, Caudell JJ (2015). Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer. Oral Oncol, 51(7), 704-8. (Read full article)
    22. Metterle L, Russell JS, Patel NS (2015). An overview of the medical management of nonmelanoma skin cancer. Curr Probl Cancer, 39(4), 226-36. (Read full article)
    23. Russell JS, Brown JM (2014). Circulating mouse Flk1+/c-Kit+/CD45- cells function as endothelial progenitors cells (EPCs) and stimulate the growth of human tumor xenografts. Mol Cancer, 13, 177. (Read full article)
    24. Russell JS, Brown JM (2013). The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. Front Physiol, 4, 157. (Read full article)
    25. Russell JS, Colevas AD (2012). The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck. Chemother Res Pract, 2012, 761518. (Read full article)
    26. Russell JS, Sawhney R, Monto A, Nanavati S, Davoren JB, Aslam R, Corvera CU (2010). Periprocedural complications by Child-Pugh class in patients undergoing transcatheter arterial embolization or chemoembolization to treat unresectable hepatocellular carcinoma at a VA medical center. Am J Surg, 200(5), 659-64. (Read full article)
    27. Camphausen K, Brady KJ, Burgan WE, Cerra MA, Russell JS, Bull EE, Tofilon PJ (2004). Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. Mol Cancer Ther, 3(4), 409-16. (Read full article)
    28. Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K, Tofilon PJ (2003). Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res, 63(21), 7377-83. (Read full article)
    29. Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ (2003). Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res, 9(10 Pt 1), 3749-55. (Read full article)
    30. Russell JS, Tofilon PJ (2002). Radiation-induced activation of nuclear factor-kappaB involves selective degradation of plasma membrane-associated I(kappa)B(alpha). Mol Biol Cell, 13(10), 3431-40. (Read full article)
    31. Russell JS, Raju U, Gumin GJ, Lang FF, Wilson DR, Huet T, Tofilon PJ (2002). Inhibition of radiation-induced nuclear factor-kappaB activation by an anti-Ras single-chain antibody fragment: lack of involvement in radiosensitization. Cancer Res, 62(8), 2318-26. (Read full article)
    32. Russell JS, Lang FF, Huet T, Janicot M, Chada S, Wilson DR, Tofilon PJ (1999). Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment. Cancer Res, 59(20), 5239-44. (Read full article)
    33. Wu X, Ting JY, Markoe AM, Landy HJ, Fiedler JA, Russell J (1996). Stereotactic dose computation and plan optimization using the convolution theorem. I. Dose computation. Stereotact Funct Neurosurg, 66 Suppl 1, 302-8. (Read full article)

    Case Report

    1. Cannon JGD, Russell JS, Kim J, Chang ALS (2018). A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery. JAAD Case Rep, 4(3), 248-250. (Read full article)
  • News & Podcasts